Impact of probiotics on necrotizing enterocolitis

Seminars in Perinatology

Volumn 41, Issue 1, 2017, Pages 41-51

  Underwood, Mark A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bifidobacterium; Human milk oligosaccharide; Lactobacillus; Necrotizing enterocolitis; Prebiotic; Premature infant; Probiotic

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

BACTERIAL GENETICS; BACTERIAL STRAIN; BIFIDOBACTERIUM; CLINICAL RESEARCH; COHORT ANALYSIS; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; INFANT FEEDING; LACTOBACILLUS; MILK; MORTALITY; MOTHER; NECROTIZING ENTEROCOLITIS; NEONATOLOGIST; PREMATURITY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; DIET THERAPY; IMMUNOLOGY; INFANT NUTRITION; INTESTINE FLORA; INTESTINE MUCOSA; MICROBIOLOGY; NEWBORN; PARENTERAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; VERY LOW BIRTH WEIGHT;

ENTEROCOLITIS, NECROTIZING; GASTROINTESTINAL MICROBIOME; HUMANS; INFANT NUTRITIONAL PHYSIOLOGICAL PHENOMENA; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; INFUSIONS, PARENTERAL; INTESTINAL MUCOSA; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85006287915     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2016.09.017     Document Type: Review

References (115)

1. 1 Hoyos, A.B., Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis 3:4 (1999), 197–202.
2. 2 Vongbhavit, K., Underwood, M.A., Prevention of necrotizing enterocolitis through manipulation of the intestinal microbiota of the premature infant. Clin Ther 38:4 (2016), 716–732.
3. 3 Xu, L., Wang, Y., Wang, Y., et al. A double-blinded randomized trial on growth and feeding tolerance with Saccharomyces boulardii CNCM I-745 in formula-fed preterm infants. J Pediatr (Rio J) 92:3 (2016), 296–301.
4. 4 Kanic, Z., Micetic Turk, D., Burja, S., Kanic, V., Dinevski, D., Influence of a combination of probiotics on bacterial infections in very low birthweight newborns. Wien Klin Wochenschr 127:suppl 5 (2015), S210–S215.
5. 5 Guthmann, F., Arlettaz Mieth, R.P., Bucher, H.U., Buhrer, C., Short courses of dual-strain probiotics appear to be effective in reducing necrotising enterocolitis. Acta Paediatr 105:3 (2016), 255–259.
6. 6 Costeloe, K., Hardy, P., Juszczak, E., Wilks, M., Millar, M.R., Probiotics in Preterm Infants Study Collaborative Group, Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial. Lancet 387:10019 (2016), 649–660.
7. 7 Oncel, M.Y., Sari, F.N., Arayici, S., et al. Lactobacillus Reuteri for the prevention of necrotising enterocolitis in very low birthweight infants: a randomised controlled trial. Arch Dis Child 99:2 (2014), F110–F115.
8. 8 Rojas, M.A., Lozano, J.M., Rojas, M.X., et al. Prophylactic probiotics to prevent death and nosocomial infection in preterm infants. Pediatrics 130:5 (2012), e1113–e1120.
9. 9 Dani, C., Biadaioli, R., Bertini, G., Martelli, E., Rubaltelli, F.F., Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate 82:2 (2002), 103–108.
10. 10 Manzoni, P., Meyer, M., Stolfi, I., et al. Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial. Early Hum Dev 90:suppl 1 (2014), S60–S65.
11. 11 Jacobs, S.E., Tobin, J.M., Opie, G.F., et al. Probiotic effects on late-onset sepsis in very preterm infants: a randomized controlled trial. Pediatrics 132:6 (2013), 1055–1062.
12. 12 Lin, H.C., Hsu, C.H., Chen, H.L., et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics 122:4 (2008), 693–700.
13. 13 Repa, A., Thanhaeuser, M., Endress, D., et al. Probiotics (Lactobacillus acidophilus and Bifidobacterium bifidum) prevent NEC in VLBW infants fed breast milk but not formula. Pediatr Res 77:2 (2015), 381–388.
14. 14 Li, D., Rosito, G., Slagle, T., Probiotics for the prevention of necrotizing enterocolitis in neonates: an 8-year retrospective cohort study. J Clin Pharm Ther 38:6 (2013), 445–449.
15. 15 Hartel, C., Pagel, J., Rupp, J., et al. Prophylactic use of Lactobacillus acidophilus/Bifidobacterium infantis probiotics and outcome in very low birth weight infants. J Pediatr, 165(2), 2014 285–289.
16. 16 Janvier, A., Malo, J., Barrington, K.J., Cohort study of probiotics in a North American neonatal intensive care unit. J Pediatr 164:5 (2014), 980–985.
17. 17 Bonsante, F., Iacobelli, S., Gouyon, J.B., Routine probiotic use in very preterm infants: retrospective comparison of two cohorts. Am J Perinatol 30:1 (2013), 41–46.
18. 18 Aceti, A., Gori, D., Barone, G., et al. Probiotics for prevention of necrotizing enterocolitis in preterm infants: systematic review and meta-analysis. Ital J Pediatr, 41, 2015, 89.
19. 19 Olsen, R., Greisen, G., Schroder, M., Brok, J., Prophylactic probiotics for preterm infants: a systematic review and meta-analysis of observational studies. Neonatology 109:2 (2016), 105–112.
20. 20 Aggarwal, S., Topaloglu, H., Kumar, S., Probiotics significantly reduce mortality in preterm newborns with necrotising enterocolitis: results of large network meta-analysis. Value Health 18:7 (2015), A576–A577.
21. 21 Lau, C.S., Chamberlain, R.S., Probiotic administration can prevent necrotizing enterocolitis in preterm infants: a meta-analysis. J Pediatr Surg 50:8 (2015), 1405–1412.
22. 22 Athalye-Jape, G., Rao, S., Patole, S., Lactobacillus reuteri DSM 17938 as a probiotic for preterm neonates: a strain-specific systematic review. J Parenter Enteral Nutr 40:6 (2016), 783–794.
23. 23 Alfaleh K., Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2014;4:CD005496.
24. 24 Collado, M.C., Rautava, S., Aakko, J., Isolauri, E., Salminen, S., Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid. Sci Rep, 6, 2016, 23129.
25. 25 Payne, M.S., Bayatibojakhi, S., Exploring preterm birth as a polymicrobial disease: an overview of the uterine microbiome. Front Immunol, 5, 2014, 595.
26. 26 Ide, M., Papapanou, P.N., Epidemiology of association between maternal periodontal disease and adverse pregnancy outcomes—systematic review. J Periodontol 84:4 suppl (2013), S181–S194.
27. 27 Donders, G.G., Van Calsteren, K., Bellen, G., et al. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG 116:10 (2009), 1315–1324.
28. 28 Yu, Z.T., Chen, C., Newburg, D.S., Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes. Glycobiology 23:11 (2013), 1281–1292.
29. 29 Huda, M.N., Lewis, Z., Kalanetra, K.M., et al. Stool microbiota and vaccine responses of infants. Pediatrics 134:2 (2014), E362–E372.
30. 30 La Rosa, P.S., Warner, B.B., Zhou, Y., et al. Patterned progression of bacterial populations in the premature infant gut. Proc Natl Acad Sci U S A 111:34 (2014), 12522–12527.
31. 31 Mai, V., Young, C.M., Ukhanova, M., et al. Fecal microbiota in premature infants prior to necrotizing enterocolitis. PLoS one, 6(6), 2011, e20647.
32. 32 Claud, E.C., Keegan, K.P., Brulc, J.M., et al. Bacterial community structure and functional contributions to emergence of health or necrotizing enterocolitis in preterm infants. Microbiome, 1(1), 2013, 20.
33. 33 Sela, D.A., Mills, D.A., The marriage of nutrigenomics with the microbiome: the case of infant-associated bifidobacteria and milk. Am J Clin Nutr 99:3 (2014), 697S–703S.
34. 34 Arboleya, S., Stanton, C., Ryan, C.A., Dempsey, E., Ross, P.R., Bosom buddies: the symbiotic relationship between infants and Bifidobacterium longum ssp. longum and ssp. infantis. Genetic and probiotic features. Ann Rev Food Sci Technol 7 (2016), 1–21.
35. 35 Garrido, D., Ruiz-Moyano, S., Lemay, D.G., Sela, D.A., German, J.B., Mills, D.A., Comparative transcriptomics reveals key differences in the response to milk oligosaccharides of infant gut-associated bifidobacteria. Sci Rep, 5, 2015, 13517.
36. 36 Ruiz-Moyano, S., Totten, S.M., Garrido, D.A., et al. Variation in consumption of human milk oligosaccharides by infant gut-associated strains of Bifidobacterium breve. Appl Environ Microbiol 79:19 (2013), 6040–6049.
37. 37 Underwood, M.A., German, J.B., Lebrilla, C.B., Mills, D.A., Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut. Jan Pediatr Res 77:1–2 (2015), 229–235.
38. 38 Underwood, M.A., Kalanetra, K.M., Bokulich, N.A., et al. A comparison of two probiotic strains of bifidobacteria in premature infants. J Pediatr, 163(6), 2013 1585–1591.
39. 39 Wickramasinghe, S., Pacheco, A.R., Lemay, D.G., Mills, D.A., Bifidobacteria grown on human milk oligosaccharides downregulate the expression of inflammation-related genes in Caco-2 cells. BMC Microbiol, 15, 2015, 172.
40. 40 Martinez, F.A., Balciunas, E.M., Converti, A., Cotter, P.D., de Souza Oliveira, R.P., Bacteriocin production by Bifidobacterium spp. A review. Biotechnol Adv 31:4 (2013), 482–488.
41. 41 Ganguli, K., Meng, D., Rautava, S., Lu, L., Walker, W.A., Nanthakumar, N., Probiotics prevent necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation. Am J Physiol Gastrointest Liver Physiol 304:2 (2013), G132–G141.
42. 42 Underwood, M.A., Arriola, J., Gerber, C.W., et al. Bifidobacterium longum subsp. infantis in experimental necrotizing enterocolitis: alterations in inflammation, innate immune response, and the microbiota. Pediatr Res 76:4 (2014), 326–333.
43. 43 Weng, M., Ganguli, K., Zhu, W., Shi, H.N., Walker, W.A., Conditioned media from Bifidobacteria infantis protects against Cronobacter sakazakii-induced intestinal inflammation in newborn mice. Am J Physiol Gastrointest Liver Physiol 306:9 (2014), 6779–6787.
44. 44 Arboleya, S., Salazar, N., Solis, G., et al. Assessment of intestinal microbiota modulation ability of Bifidobacterium strains in in vitro fecal batch cultures from preterm neonates. Anaerobe 19 (2013), 9–16.
45. 45 Khailova, L., Dvorak, K., Arganbright, K.M., et al. Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 297:5 (2009), G940–G949.
46. 46 Khailova, L., Mount Patrick, S.K., Arganbright, K.M., Halpern, M.D., Kinouchi, T., Dvorak, B., Bifidobacterium bifidum reduces apoptosis in the intestinal epithelium in necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 299:5 (2010), G1118–G1127.
47. 47 Underwood, M.A., Kananurak, A., Coursodon, C.F., et al. Bifidobacterium bifidum in a rat model of necrotizing enterocolitis: antimicrobial peptide and protein responses. Pediatr Res 71:5 (2012), 546–551.
48. 48 Satoh, T., Izumi, H., Iwabuchi, N., et al. Bifidobacterium breve prevents necrotising enterocolitis by suppressing inflammatory responses in a preterm rat model. Benef Microbes 7:1 (2015), 1–8.
49. 49 Izumi, H., Minegishi, M., Sato, Y., Shimizu, T., Sekine, K., Takase, M., Bifidobacterium breve alters immune function and ameliorates DSS-induced inflammation in weanling rats. Pediatr Res 78:4 (2015), 407–416.
50. 50 Bidart, G.N., Rodriguez-Diaz, J., Monedero, V., Yebra, M.J., A unique gene cluster for the utilization of the mucosal and human milk-associated glycans galacto-N-biose and lacto-N-biose in Lactobacillus casei. Mol Microbiol 93:3 (2014), 521–538.
51. 51 Bidart, G.N., Rodriguez-Diaz, J., Yebra, M.J., The extracellular wall-bound beta-N-acetylglucosaminidase from Lactobacillus casei is involved in the metabolism of the human milk oligosaccharide lacto-N-triose. Appl Environ Microbiol 82:2 (2016), 570–577.
52. 52 Kacerovsky, M., Vrbacky, F., Kutova, R., et al. Cervical microbiota in women with preterm prelabor rupture of membranes. PLoS one, 10(5), 2015, e0126884.
53. 53 Elawadli, I., Brisbin, J.T., Mallard, B.A., Griffiths, M.W., Corredig, M., Sharif, S., Differential effects of lactobacilli on activation and maturation of mouse dendritic cells. Benef Microbes 5:3 (2014), 323–334.
54. 54 Goncalves, F.L., Soares, L.M., Figueira, R.L., Simoes, A.L., Gallindo, R.M., Sbragia, L., Evaluation of the expression of I-FABP and L-FABP in a necrotizing enterocolitis model after the use of Lactobacillus acidophilus. J Pediatr Surg 50:4 (2015), 543–549.
55. 55 Nandakumar, R., Talapatra, K., Quantitative profiling of bacteriocins present in dairy-free probiotic preparations of Lactobacillus acidophilus by nanoliquid chromatography-tandem mass spectrometry. J Dairy Sci 97:4 (2014), 1999–2008.
56. 56 Awaisheh, S.S., Al-Nabulsi, A.A., Osaili, T.M., Ibrahim, S., Holley, R., Inhibition of Cronobacter sakazakii by heat labile bacteriocins produced by probiotic LAB isolated from healthy infants. J Food Sci 78:9 (2013), M1416–M1420.
57. 57 Anjum, N., Maqsood, S., Masud, T., Ahmad, A., Sohail, A., Momin, A., Lactobacillus acidophilus: characterization of the species and application in food production. Crit Rev Food Sci Nutr 54:9 (2014), 1241–1251.
58. 58 Borthakur, A., Bhattacharyya, S., Kumar, A., Anbazhagan, A.N., Tobacman, J.K., Dudeja, P.K., Lactobacillus acidophilus alleviates platelet-activating factor-induced inflammatory responses in human intestinal epithelial cells. PLoS one, 8(10), 2013, e75664.
59. 59 Kumar, A., Alrefai, W.A., Borthakur, A., Dudeja, P.K., Lactobacillus acidophilus counteracts enteropathogenic E. coli-induced inhibition of butyrate uptake in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 309:7 (2015), G602–G607.
60. 60 Guo, S., Guo, Y., Ergun, A., Lu, L., Walker, W.A., Ganguli, K., Secreted metabolites of Bifidobacterium infantis and Lactobacillus acidophilus protect immature human enterocytes from IL-1beta-induced inflammation: a transcription profiling analysis. PLoS One, 10(4), 2015, e0124549.
61. 61 Spinler, J.K., Taweechotipatr, M., Rognerud, C.L., Ou, C.N., Tumwasorn, S., Versalovic, J., Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe 14:3 (2008), 166–171.
62. 62 Yang, Y., Zhao, X., Le, M.H., Zijlstra, R.T., Ganzle, M.G., Reutericyclin producing Lactobacillus reuteri modulates development of fecal microbiota in weanling pigs. Front Microbiol, 6, 2015, 762.
63. 63 Lin, Y.P., Thibodeaux, C.H., Pena, J.A., Ferry, G.D., Versalovic, J., Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 14:8 (2008), 1068–1083.
64. 64 Liu, Y., Fatheree, N.Y., Mangalat, N., Rhoads, J.M., Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-kappaB signaling in the intestine. Am J Physiol Gastrointest Liver Physiol 302:6 (2012), G608–G617.
65. 65 Liu, Y., Fatheree, N.Y., Dingle, B.M., Tran, D.Q., Rhoads, J.M., Lactobacillus reuteri DSM 17938 changes the frequency of Foxp3+ regulatory T cells in the intestine and mesenteric lymph node in experimental necrotizing enterocolitis. PLoS One, 8(2), 2013, e56547.
66. 66 Kunze, W.A., Mao, Y.K., Wang, B., et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. J Cell Mol Med 13:8B (2009), 2261–2270.
67. 67 Wu, R.Y., Pasyk, M., Wang, B., et al. Spatiotemporal maps reveal regional differences in the effects on gut motility for Lactobacillus reuteri and rhamnosus strains. Neurogastroenterol Motil 25:3 (2013), e205–e214.
68. 68 Fayol-Messaoudi, D., Berger, C.N., Coconnier-Polter, M.H., Lievin-Le Moal, V., Servin, A.L., pH-, lactic acid-, and non-lactic acid-dependent activities of probiotic Lactobacilli against Salmonella enterica Serovar Typhimurium. Oct Appl Environ Microbiol 71:10 (2005), 6008–6013.
69. 69 Mirpuri, J., Sotnikov, I., Myers, L., et al. Lactobacillus rhamnosus (LGG) regulates IL-10 signaling in the developing murine colon through upregulation of the IL-10R2 receptor subunit. PLoS One, 7(12), 2012, e51955.
70. 70 Lin, P.W., Nasr, T.R., Berardinelli, A.J., Kumar, A., Neish, A.S., The probiotic Lactobacillus GG may augment intestinal host defense by regulating apoptosis and promoting cytoprotective responses in the developing murine gut. Pediatr Res 64:5 (2008), 511–516.
71. 71 Patel, R.M., Myers, L.S., Kurundkar, A.R., Maheshwari, A., Nusrat, A., Lin, P.W., Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am J Pathol 180:2 (2012), 626–635.
72. 72 Yan, F., Polk, D.B., Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases. Gut Microbes 3:1 (2012), 25–28.
73. 73 Good, M., Sodhi, C.P., Ozolek, J.A., et al. Lactobacillus rhamnosus HN001 decreases the severity of necrotizing enterocolitis in neonatal mice and preterm piglets: evidence in mice for a role of TLR9. Am J Physiol Gastrointest Liver Physiol 306:11 (2014), G1021–G1032.
74. 74 Chioukh, F.Z., Ben Hmida, H., Ben Ameur, K., Toumi, A., Monastiri, K., Saccharomyces cerevisiae fungemia in a premature neonate treated receiving probiotics. Med Mal Infect 43:8 (2013), 359–360.
75. 75 Belet, N., Dalgic, N., Oncel, S., et al. Catheter-related fungemia caused by Saccharomyces cerevisiae in a newborn. Pediatr Infect Dis J, 24(12), 2005, 1125.
76. 76 Perapoch, J., Planes, A.M., Querol, A., et al. Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura. Eur J Clin Microbiol Infect Dis 19:6 (2000), 468–470.
77. 77 Dani, C., Coviello, C.C., Corsini, I.I., Arena, F., Antonelli, A., Rossolini, G.M., Lactobacillus sepsis and probiotic therapy in newborns: two new cases and literature review. AJP Rep 6:1 (2016), e25–e29.
78. 78 Brecht, M., Garg, A., Longstaff, K., Cooper, C., Andersen, C., Lactobacillus sepsis following a laparotomy in a preterm infant: a note of caution. Neonatology 109:3 (2016), 186–189.
79. 79 Kunz, A.N., Noel, J.M., Fairchok, M.P., Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 38:4 (2004), 457–458.
80. 80 Land, M.H., Rouster-Stevens, K., Woods, C.R., Cannon, M.L., Cnota, J., Shetty, A.K., Lactobacillus sepsis associated with probiotic therapy. Pediatrics 115:1 (2005), 178–181.
81. 81 De Groote, M.A., Frank, D.N., Dowell, E., Glode, M.P., Pace, N.R., Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 24:3 (2005), 278–280.
82. 82 Sadowska-Krawczenko, I., Paprzycka, M., Korbal, P., et al. Lactobacillus rhamnosus GG suspected infection in a newborn with intrauterine growth restriction. Benef Microbes 5:4 (2014), 397–402.
83. 83 Bertelli, C., Pillonel, T., Torregrossa, A., et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 60:6 (2015), 924–927.
84. 84 Zbinden, A., Zbinden, R., Berger, C., Arlettaz, R., Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 107:1 (2015), 56–59.
85. 85 Ohishi, A., Takahashi, S., Ito, Y., et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr 156:4 (2010), 679–681.
86. 86 Lee, M.R., Tsai, C.J., Liang, S.K., Lin, C.K., Huang, Y.T., Hsueh, P.R., Clinical characteristics of bacteraemia caused by Lactobacillus spp. and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2000–2014. Int J Antimicrob Agents 46:4 (2015), 439–445.
87. 87 Gouriet, F., Million, M., Henri, M., Fournier, P.E., Raoult, D., Lactobacillus rhamnosus bacteremia: an emerging clinical entity. European J Clin Microbiol Infect Dis 31:9 (2012), 2469–2480.
88. 88 Cannon, J.P., Lee, T.A., Bolanos, J.T., Danziger, L.H., Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis 24:1 (2005), 31–40.
89. 89 Salminen, M.K., Tynkkynen, S., Rautelin, H., et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 35:10 (2002), 1155–1160.
90. 90 Sullivan, A., Nord, C.E., Probiotic lactobacilli and bacteraemia in Stockholm. Scand J Infect Dis 38:5 (2006), 327–331.
91. 91 Maziade, P.J., Pereira, P., Goldstein, E.J., A decade of experience in primary prevention of Clostridium difficile infection at a Community Hospital using the probiotic combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clin Infect Dis 60:suppl 2 (2015), S144–S147.
92. 92 Salvana, E.M., Frank, M., Lactobacillus endocarditis: case report and review of cases reported since 1992. J Infect 53:1 (2006), e5–e10.
93. 93 Goldstein, E.J., Tyrrell, K.L., Citron, D.M., Lactobacillus species: taxonomic complexity and controversial susceptibilities. Clin Infect Dis 60:Suppl 2 (2015), S98–107.
94. 94 Zhou, J.S., Pillidge, C.J., Gopal, P.K., Gill, H.S., Antibiotic susceptibility profiles of new probiotic Lactobacillus and Bifidobacterium strains. Int J Food Microbiol 98:2 (2005), 211–217.
95. 95 Weber, E., Reynaud, Q., Suy, F., et al. Bifidobacterium species bacteremia: risk factors in adults and infants. Aug 1 Clin Infect Dis 61:3 (2015), 482–484.
96. 96 Aroutcheva, A., Auclair, J., Frappier, M., et al. Importance of molecular methods to determine whether a probiotic is the source of lactobacillus bacteremia. Probiotics Antimicrob Proteins 8:1 (2016), 31–40.
97. 97 Xiao, J.Z., Takahashi, S., Odamaki, T., Yaeshima, T., Iwatsuki, K., Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem 74:2 (2010), 336–342.
98. 98 Masco, L., Van Hoorde, K., De Brandt, E., Swings, J., Huys, G., Antimicrobial susceptibility of Bifidobacterium strains from humans, animals and probiotic products. J Antimicrob Chemother 58:1 (2006), 85–94.
99. 99 Vallabhaneni, S., Walker, T.A., Lockhart, S.R., et al. Notes from the field: fatal gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement—Connecticut, 2014. MMWR Morb Mortal Wkly Rep 64:6 (2015), 155–156.
100. 100 Lewis, Z.T., Shani, G., Masarweh, C.F., et al. Validating bifidobacterial species and subspecies identity in commercial probiotic products. Pediatr Res 79:3 (2016), 445–452.
101. 101 Marcobal, A., Underwood, M.A., Mills, D.A., Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis. J Pediatr Gastroenterol Nutr 46:5 (2008), 608–611.
102. 102 Janvier, A., Lantos, J., Barrington, K., The politics of probiotics: probiotics, necrotizing enterocolitis and the ethics of neonatal research. Acta Paediatr 102:2 (2013), 116–118.
103. 103 Tarnow-Mordi, W., Cruz, M., Morris, J., Design and conduct of a large obstetric or neonatal randomized controlled trial. Semin Fetal Neonatal Med 20:6 (2015), 389–402.
104. 104 Hays, S., Jacquot, A., Gauthier, H., et al. Probiotics and growth in preterm infants: a randomized controlled trial, PREMAPRO study. Clin Nutr 35:4 (2015), 802–811.
105. 105 Underwood, M.A., Salzman, N.H., Bennett, S.H., et al. A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants: impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids. J Pediatr Gastroenterol Nutr 48:2 (2009), 216–225.
106. 106 Patel, R.M., Denning, P.W., Therapeutic use of prebiotics, probiotics, and postbiotics to prevent necrotizing enterocolitis: what is the current evidence?. Clin Perinatol 40:1 (2013), 11–25.
107. 107 Wu, S.F., Chiu, H.Y., Chen, A.C., Lin, H.Y., Lin, H.C., Caplan, M., Efficacy of different probiotic combinations on death and necrotizing enterocolitis in a premature rat model. J Pediatr Gastroenterol Nutr 57:1 (2013), 23–28.
108. 108 Shiou, S.R., Yu, Y., Guo, Y., et al. Synergistic protection of combined probiotic conditioned media against neonatal necrotizing enterocolitis-like intestinal injury. PLoS One, 8(5), 2013, e65108.
109. 109 Barrington, K.J., Janvier, A., Reply: to PMID 24411521. J Pediatr 166:2 (2015), 502–503.
110. 110 Schreck Bird, A., Gregory, P.J., Jalloh, M.A., Risoldi Cochrane, Z., Hein, D.J., Probiotics for the treatment of infantile colic: a systematic review. J Pharm Pract, 2016 Mar 2, e-pub ahead of print.
111. 111 Benor, S., Marom, R., Ben Tov, A., Armoni Domany, K., Zaidenberg-Israeli, G., Dollberg, S., Probiotic supplementation in mothers of very low birth weight infants. Am J Perinatol 31:6 (2014), 497–504.
112. 112 Blanton, L.V., Charbonneau, M.R., Salih, T., et al. Gut bacteria that prevent growth impairments transmitted by microbiota from malnourished children. Science, 351(6275), 2016.
113. 113 Morrow, A.L., Meinzen-Derr, J., Huang, P., et al. Fucosyltransferase 2 non-secretor and low secretor status predicts severe outcomes in premature infants. J Pediatr 158:5 (2011), 745–751.
114. 114 Hartel, C., Hartz, A., Pagel, J., et al. NOD2 loss-of-function mutations and risks of necrotizing enterocolitis or focal intestinal perforation in very low-birth-weight infants. Inflamm Bowel Dis 22:2 (2016), 249–256.
115. 115 Underwood, M.A., Gaerlan, S., De Leoz, M.L., et al. Human milk oligosaccharides in premature infants: absorption, excretion, and influence on the intestinal microbiota. Pediatr Res 78:6 (2015), 670–677.